Ethris GmbH, a biotech company specializing in RNA therapeutics, has teamed up with Thermo Fisher Scientific to offer a complete mRNA solution for drug developers. This partnership combines Ethris's advanced mRNA technologies, including their unique Stabilized Non-Immunogenic mRNA (SNIM® RNA), with Thermo Fisher's extensive manufacturing capabilities. The goal is to make it easier for biopharmaceutical companies worldwide to quickly move mRNA-based medicines from research to clinical trials.

This collaboration will also help improve Ethris's technology, which has already shown promising results in early clinical trials for their lead asthma drug, ETH47. ETH47, administered via nasal spray, demonstrated safe and localized production of a therapeutic protein, confirming the potential of Ethris's SNIM® RNA to be repeatedly administered for sustained protein production, offering a versatile platform for new medicines and vaccines. Thermo Fisher's involvement expands their services to include cutting-edge mRNA manufacturing, aiming to accelerate the delivery of life-changing treatments to patients.